Nick Thatcher

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher, Alex Y. Chang, Purvish M. Parikh et al. · The Lancet · 2005 · 2.1K citations

Iressa Survival Evaluation, Medicine, Cancer Management +6

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn et al. · Journal of Clinical Oncology · 2006 · 702 citations · Full text

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Charles Butts, Mark A. Socinski, Paul Mitchell et al. · The Lancet Oncology · 2013 · 520 citations · Full text

Oncology, Medicine, Metronomic Therapy +8

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Nick Thatcher, Fred R. Hirsch, Alexander Luft et al. · The Lancet Oncology · 2015 · 472 citations · Full text

First-line Therapy, Medicine, Pathology +7

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

Lucio Crinò, Éric Dansin, Pilar Garrido et al. · The Lancet Oncology · 2010 · 268 citations

Medicine, Phase 4, First-line Bevacizumab-based Therapy +5